Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study

• Published in: The lancet oncology Vol. 18; no. 4; pp. 525 - 534
• Main Authors: Halperin, Daniel M, Shen, Chan, Dasari, Arvind, Xu, Ying, Chu, Yiyi, Zhou, Shouhao, Shih, Ya-Chen Tina, Yao, James C
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2017; Elsevier Limited
• Subjects: Aged; Aged, 80 and over; Amines; Chemotherapy; Combined Modality Therapy - adverse effects; Diarrhea; Diarrhea - epidemiology; Diarrhea - etiology; Epidemiology; Female; Follow-Up Studies; Hematology, Oncology, and Palliative Medicine; Humans; Lung cancer; Male; Malignant Carcinoid Syndrome - epidemiology; Malignant Carcinoid Syndrome - etiology; Medical diagnosis; Medical prognosis; Medicare; Metastasis; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors - complications; Neuroendocrine Tumors - diagnosis; Neuroendocrine Tumors - therapy; Octreotide; Pancreas; Pancreatic cancer; Patients; Population studies; Population-based studies; Prognosis; Quality of life; Radiation therapy; Serotonin; Studies; Surgery; Survival; Survival analysis; Survival Rate; Texas - epidemiology; Tumors; United States > US

Neuroendocrine tumours (NETs) can secrete bioactive amines into the bloodstream, causing carcinoid syndrome, with symptoms including flushing and diarrhoea. However, carcinoid syndrome frequency in the NET population has never been rigorously assessed, nor has its relationship to presenting clinicop...